254 related articles for article (PubMed ID: 16443250)
1. Protection from the toxicity of diisopropylfluorophosphate by adeno-associated virus expressing acetylcholinesterase.
Li B; Duysen EG; Poluektova LY; Murrin LC; Lockridge O
Toxicol Appl Pharmacol; 2006 Jul; 214(2):152-65. PubMed ID: 16443250
[TBL] [Abstract][Full Text] [Related]
2. Delivery of human acetylcholinesterase by adeno-associated virus to the acetylcholinesterase knockout mouse.
Hrabovska A; Duysen EG; Sanders JD; Murrin LC; Lockridge O
Chem Biol Interact; 2005 Dec; 157-158():71-8. PubMed ID: 16243306
[TBL] [Abstract][Full Text] [Related]
3. Gene transfer of acetylcholinesterase protects the knockout mouse from the toxicity of DFP.
Li B; Duysen EG; Lockridge O
J Mol Neurosci; 2006; 30(1-2):79-80. PubMed ID: 17192637
[TBL] [Abstract][Full Text] [Related]
4. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase.
Xie W; Stribley JA; Chatonnet A; Wilder PJ; Rizzino A; McComb RD; Taylor P; Hinrichs SH; Lockridge O
J Pharmacol Exp Ther; 2000 Jun; 293(3):896-902. PubMed ID: 10869390
[TBL] [Abstract][Full Text] [Related]
5. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.
Boudinot E; Taysse L; Daulon S; Chatonnet A; Champagnat J; Foutz AS
Pharmacol Biochem Behav; 2005 Jan; 80(1):53-61. PubMed ID: 15652380
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
7. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice.
Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J
Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011
[TBL] [Abstract][Full Text] [Related]
8. Resistance to organophosphorus agent toxicity in transgenic mice expressing the G117H mutant of human butyrylcholinesterase.
Wang Y; Boeck AT; Duysen EG; Van Keuren M; Saunders TL; Lockridge O
Toxicol Appl Pharmacol; 2004 May; 196(3):356-66. PubMed ID: 15094306
[TBL] [Abstract][Full Text] [Related]
9. Histone acetylase inhibitor trichostatin A induces acetylcholinesterase expression and protects against organophosphate exposure.
Curtin BF; Tetz LM; Compton JR; Doctor BP; Gordon RK; Nambiar MP
J Cell Biochem; 2005 Nov; 96(4):839-49. PubMed ID: 16149071
[TBL] [Abstract][Full Text] [Related]
10. Increased diisopropylfluorophosphate-induced toxicity in mu-opioid receptor knockout mice.
Tien LT; Fan LW; Ma T; Loh HH; Ho IK
J Neurosci Res; 2004 Oct; 78(2):259-67. PubMed ID: 15378609
[TBL] [Abstract][Full Text] [Related]
11. Differential mRNA expression of acetylcholinesterase in the central nervous system of rats with acute and chronic exposure of sarin & physostigmine.
Bansal I; Waghmare CK; Anand T; Gupta AK; Bhattacharya BK
J Appl Toxicol; 2009 Jul; 29(5):386-94. PubMed ID: 19283689
[TBL] [Abstract][Full Text] [Related]
12. Synaptic remodeling at the skeletal neuromuscular junction of acetylcholinesterase knockout mice and its physiological relevance.
Girard E; Barbier J; Chatonnet A; Krejci E; Molgó J
Chem Biol Interact; 2005 Dec; 157-158():87-96. PubMed ID: 16274683
[TBL] [Abstract][Full Text] [Related]
13. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma.
Li B; Sedlacek M; Manoharan I; Boopathy R; Duysen EG; Masson P; Lockridge O
Biochem Pharmacol; 2005 Nov; 70(11):1673-84. PubMed ID: 16213467
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity analysis on a physiologically-based pharmacokinetic and pharmacodynamic model for diisopropylfluorophosphate-induced toxicity in mice and rats.
Chen K; Teo S; Seng KY
Toxicol Mech Methods; 2009 Oct; 19(8):486-97. PubMed ID: 19788408
[TBL] [Abstract][Full Text] [Related]
15. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter.
Sun B; Zhang H; Franco LM; Brown T; Bird A; Schneider A; Koeberl DD
Mol Ther; 2005 Jun; 11(6):889-98. PubMed ID: 15922959
[TBL] [Abstract][Full Text] [Related]
16. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity.
Hartmann J; Kiewert C; Duysen EG; Lockridge O; Greig NH; Klein J
J Neurochem; 2007 Mar; 100(5):1421-9. PubMed ID: 17212694
[TBL] [Abstract][Full Text] [Related]
17. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration.
Bostick B; Ghosh A; Yue Y; Long C; Duan D
Gene Ther; 2007 Nov; 14(22):1605-9. PubMed ID: 17898796
[TBL] [Abstract][Full Text] [Related]
18. Fullerene antioxidants decrease organophosphate-induced acetylcholinesterase inhibition in vitro.
Ehrich M; Van Tassell R; Li Y; Zhou Z; Kepley CL
Toxicol In Vitro; 2011 Feb; 25(1):301-7. PubMed ID: 20888407
[TBL] [Abstract][Full Text] [Related]
19. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model.
Xu F; Ding E; Liao SX; Migone F; Dai J; Schneider A; Serra D; Chen YT; Amalfitano A
Gene Ther; 2004 Nov; 11(21):1590-8. PubMed ID: 15356673
[TBL] [Abstract][Full Text] [Related]
20. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia.
Koeberl DD; Sun BD; Damodaran TV; Brown T; Millington DS; Benjamin DK; Bird A; Schneider A; Hillman S; Jackson M; Beaty RM; Chen YT
Gene Ther; 2006 Sep; 13(17):1281-9. PubMed ID: 16672983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
